Equities Analysts Issue Forecasts for PCRX FY2024 Earnings

Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) - Zacks Research raised their FY2024 EPS estimates for Pacira BioSciences in a report issued on Tuesday, January 14th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $2.63 for the year, up from their prior forecast of $2.60. The consensus estimate for Pacira BioSciences' current full-year earnings is $2.38 per share. Zacks Research also issued estimates for Pacira BioSciences' Q4 2024 earnings at $0.61 EPS, Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.56 EPS, Q4 2025 earnings at $0.60 EPS, FY2025 earnings at $2.36 EPS, Q1 2026 earnings at $0.63 EPS, Q2 2026 earnings at $0.64 EPS, Q3 2026 earnings at $0.66 EPS, Q4 2026 earnings at $0.79 EPS and FY2026 earnings at $2.72 EPS.

PCRX has been the topic of a number of other reports. Jefferies Financial Group raised their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, September 24th. Needham & Company LLC lifted their price target on shares of Pacira BioSciences from $22.00 to $30.00 and gave the company a "buy" rating in a research report on Monday. Royal Bank of Canada reiterated a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday. Barclays reduced their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an "equal weight" rating on the stock in a report on Tuesday, November 12th. Finally, HC Wainwright reiterated a "buy" rating and issued a $39.00 price target on shares of Pacira BioSciences in a report on Wednesday, December 4th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $24.50.

Pacira BioSciences Trading Up 1.4 %

Pacira BioSciences stock traded up $0.30 during midday trading on Friday, reaching $22.36. The stock had a trading volume of 930,322 shares, compared to its average volume of 789,778. The stock's 50-day simple moving average is $18.71 and its 200 day simple moving average is $17.51. Pacira BioSciences has a twelve month low of $11.16 and a twelve month high of $34.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The stock has a market capitalization of $1.03 billion, a PE ratio of -11.01 and a beta of 0.76.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC increased its holdings in Pacira BioSciences by 495.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company's stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. CWM LLC grew its position in shares of Pacira BioSciences by 713.6% during the third quarter. CWM LLC now owns 6,517 shares of the company's stock worth $98,000 after buying an additional 5,716 shares in the last quarter. Virtus Investment Advisers Inc. bought a new stake in shares of Pacira BioSciences in the third quarter worth $98,000. China Universal Asset Management Co. Ltd. raised its holdings in Pacira BioSciences by 62.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,872 shares of the company's stock valued at $134,000 after acquiring an additional 3,404 shares in the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in Pacira BioSciences during the 2nd quarter valued at $140,000. Institutional investors and hedge funds own 99.73% of the company's stock.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.